Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter Phase III, Randomized Study to Evaluate Treatment Customized According to RAP80 and BRCA1 Assessment in Patients With Advanced Non-small-cell Lung Cancer

Next Previous
Trial Profile

Multicenter Phase III, Randomized Study to Evaluate Treatment Customized According to RAP80 and BRCA1 Assessment in Patients With Advanced Non-small-cell Lung Cancer

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary)
  • Indications Carcinoma; Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms BREC

    • Most Recent Events

    • 22 Nov 2018 Results assessing association of PALB2 messenger RNA expression with platinum-docetaxel efficacy published in the Journal of Thoracic Oncology.
    • 31 May 2013 Planned interim results (cut-off 15 October 2012; n=279) presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 31 May 2013 Based on the negative results for PFS at the interim analysis, accrual has been closed according to the abstract presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top